WASHINGTON (Great Lakes News) – On Tuesday, Pfizer announced its experimental COVID-19 pill appears effective against the omicron variant.

In addition, the pharmaceutical giant said full results of its 2250-person study confirmed the drug reduced combined hospitalizations and deaths by roughly 89-percent among high-risk adults when taken shortly after initial onset of COVID-19 symptoms.

MORE NEWS: Semi Driver Busted on Mackinac Bridge with 27 Illegal Weapons, Including Loaded Guns and Sword

The Food and Drug Administration is expected to rule on whether to authorize Pfizer’s pill and a competing pill from Merck soon.